You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 東陽光藥(1558.HK)跌逾6% 核心產品競爭格局嚴峻 產品單一化隱憂持續
格隆匯 07-29 14:10
格隆匯7月29日丨東陽光藥(1558.HK)跌逾6%,報12.14港元,總市值107億港元。交銀國際發佈報告稱,東陽光藥發佈盈利預警,預期2020年上半年歸母淨利潤同比下降35-45%,低於該行的預期,主要受新冠疫情影響,院內治療量及藥品銷量下降所致。公司核心產品可威競爭格局嚴峻,羅氏創新流感藥Xofluza上市及原研藥專利到期構成威脅,該行預計2020/21/22年可威銷售額同比變動-28%/12%/14%,產品單一化隱憂持續。該行調低東陽光藥2020/21/22年盈利預測31-34%,評級從買入降為中性,目標價從18.00港元降至14.70港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account